Sarepta Therapeutics Is Maintained at Sell by Citigroup

robot
Abstract generation in progress

Citigroup has reiterated its “Sell” rating for Sarepta Therapeutics (SRPT). This maintenance of a negative outlook indicates the firm’s continued skepticism regarding the company, despite potential market developments. The analyst’s current stance suggests that challenges or fundamental concerns may persist for Sarepta.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin